Skip to main content Skip to section navigation Skip to footer
French

Acasti Pharma Inc.

  • English
  • About Us
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Clinical Pipeline
    • GTX-104
    • GTX-102
    • GTX-101
  • Investor Relations
    • Overview
    • News / Events
    • Company Info
    • Financial Results
    • Stock Data
    • Regulatory Filings
    • Governance
  • Newsroom
  • Careers
  • Contact
  • French

Press Releases

Investor Relations

Investor Relations

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Media
    • IR Calendar
    • Email Alerts
    • Grace Merger Conference Call
  • Company Info
    • Overview
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • NASDAQ: ACST
    • TSXV: ACST
    • Analyst Coverage
  • Regulatory Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Section 16 Filings
    • SEDAR
    • Tax Notifications
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News / Events

  • Overview
  • Press Releases
  • Media
  • IR Calendar
  • Email Alerts
  • Grace Merger Conference Call

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

Mar 13, 2023

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference

Mar 8, 2023

Acasti Pharma Recognizes Rare Disease Day

Feb 28, 2023

Acasti Pharma Reports Third Quarter 2023 Operational Results

Feb 14, 2023

Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023

Feb 7, 2023

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Jan 25, 2023

Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

Jan 24, 2023

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

Jan 13, 2023

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

Jan 5, 2023

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Dec 28, 2022
rss_feed News RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...25
Next
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
© 2023 Acasti Pharma Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap